<VariationArchive RecordType="classified" VariationID="1071859" VariationName="NC_000016.9:g.(?_10273845)_(10274268_?)del" VariationType="Deletion" Accession="VCV001071859" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2021-05-10" MostRecentSubmission="2021-05-10">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1057722" VariationID="1071859">
      <GeneList>
        <Gene Symbol="GRIN2A" FullName="glutamate ionotropic receptor NMDA type subunit 2A" GeneID="2903" HGNC_ID="HGNC:4585" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="9753404" stop="10182908" display_start="9753404" display_stop="10182908" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="9847264" stop="10276610" display_start="9847264" display_stop="10276610" Strand="-" />
          </Location>
          <OMIM>138253</OMIM>
          <Haploinsufficiency last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000016.9:g.(?_10273845)_(10274268_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="10273845" innerStop="10274268" display_start="10273845" display_stop="10274268" variantLength="424" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_10273845)_(10274268_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_10273845)_(10274268_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.9:g.(?_10273845)_(10274268_?)del AND Landau-Kleffner syndrome" Accession="RCV001384402" Version="1">
        <ClassifiedConditionList TraitSetID="12189">
          <ClassifiedCondition DB="MedGen" ID="C0282512">Landau-Kleffner syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-09-30" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-09-30" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2021-05-10">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">23933819</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23933820</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12189" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5374" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Landau-Kleffner syndrome</ElementValue>
                <XRef ID="Landau-Kleffner+syndrome/4080" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009509" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epilepsy with neurodevelopmental defects</ElementValue>
                <XRef ID="Epilepsy+with+neurodevelopmental+defects/8322" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APHASIA, ACQUIRED, WITH EPILEPSY</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired aphasia with convulsive disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired epileptiform aphasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LKS</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">FESD</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ADRESD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RESDAD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Encephalopathy with Epilepsy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Speech Disorders and Epilepsy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GRIN2A-related speech disorders and epilepsy are characterized by speech disorders in all affected individuals and a range of epilepsy syndromes present in about 90%. Severe speech disorders observed can include dysarthria and speech dyspraxia, and both receptive and expressive language delay/regression; more mildly affected individuals may display subtly impaired intelligibility of conversational speech. Epilepsy features include seizure onset usually between ages three and six years, focal epilepsy with language and/or global developmental regression, and electroencephalogram (EEG) showing continuous spike-and-wave discharges in sleep or very active centrotemporal discharges. Seizure types include seizures associated with aura of perioral paresthesia, focal or focal motor seizures (often evolving to generalized tonic-clonic), and atypical absence seizures. Epilepsy syndromes can include: Landau-Kleffner syndrome (LKS), epileptic encephalopathy with continuous spike-and-wave during sleep (ECSWS), childhood epilepsy with centrotemporal spikes (CECTS), atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD), and infantile-onset epileptic encephalopathy.</Attribute>
                <XRef ID="NBK385627" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6855" />
                <XRef ID="6855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Disorders</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">27683935</ID>
                <ID Source="BookShelf">NBK385627</ID>
              </Citation>
              <XRef ID="1945" DB="Orphanet" />
              <XRef ID="725" DB="Orphanet" />
              <XRef ID="98818" DB="Orphanet" />
              <XRef ID="C0282512" DB="MedGen" />
              <XRef ID="MONDO:0009509" DB="MONDO" />
              <XRef Type="MIM" ID="245570" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3109518" SubmissionDate="2021-01-07" DateLastUpdated="2021-05-10" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000833.4_16_Deletion (exon 3)|MedGen:C1832814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001583876" DateUpdated="2021-05-10" DateCreated="2021-05-10" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23933819</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23933820</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon 3 of the GRIN2A gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 3 of the GRIN2A gene. This is expected to result in an absent or disrupted protein product. This variant has not been reported in the literature in individuals with GRIN2A-related conditions. Loss-of-function variants in GRIN2A are known to be pathogenic (PMID: 23933819, 23933820). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GRIN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_10273845)_(10274268_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1832814" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3109518" TraitType="Disease" MappingType="XRef" MappingValue="C1832814" MappingRef="MedGen">
        <MedGen CUI="C0282512" Name="Landau-Kleffner syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

